HLA-DR protein status predicts survival in patients with diffuse large B-cell lymphoma treated on the MACOP-B chemotherapy regimen

Leukemia and Lymphoma

Volumn 48, Issue 3, 2007, Pages 542-546

  Rimsza, Lisa M ^a   Farinha, Pedro ^b   Fuchs, Deborah A ^a   Masoudi, Hamid ^b   Connors, Joseph M ^b   Gascoyne, Randy D ^b  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Diffuse large B cell lymphoma; HLA DR; Major histocompatibility; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FOLINIC ACID; HLA DR ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; METHOTREXATE; PREDNISONE; VINCRISTINE;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ASSESSMENT TOOL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERNATIONAL PROGNOSTIC INDEX; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; SCORING SYSTEM;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HLA-DR ANTIGENS; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; METHOTREXATE; MIDDLE AGED; PREDNISOLONE; PROGNOSIS; SURVIVAL RATE; VINCRISTINE;

EID: 33947660517     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190601078605     Document Type: Article

References (18)

1. Rosenwald, A., Wright, G., Chan, W. C., J. M., Campo, E. and Fisher, R. I. (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med, 346, pp. 1937-1947.
2. Shipp, M. A., Ross, K. N., Tamayo, P., Weng, A. P., Kutok, J. L. and Aguiar, R. C. (2002) Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med, 8, pp. 68-74.
3. Ting, J. P. and Zhu, X. S. (1999) Class II MHC genes: A model gene regulatory system with great biologic consequences. Microbes Infect, 1, pp. 855-861.
4. Rimsza, L. M., Roberts, R. A., Miller, T. P., Unger, J. M., LeBlanc, M. and Braziel, R. M. (2004) Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: A follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood, 103, pp. 4251-4258.
5. List, A. F., Spier, C. M., Miller, T. P. and Grogan, T. M. (1993) Deficient tumor-infiltrating T-lymphocyte response in malignant lymphoma: Relationship to HLA expression and host immunocompetence. Leukemia, 7, pp. 398-403.
6. Miller, T. P., Lippman, S. M., Spier, C. M. Slymen, D. J. and Grogan, T. M. (1988) HLA-DR (Ia) immune phenotype predicts outcome for patients with diffuse large cell lymphoma. J Clin Invest, 82, pp. 370-372.
7. Stopeck, A. T., Gessner, A., Miller, T. P., Hersh, E. M., Johnson, C. S. and Cui, H. (2000) Loss of B7.2 (CD86) and intracellular adhesion molecule 1 (CD54) expression is associated with decreased tumor-infiltrating T lymphocytes in diffuse B-cell large-cell lymphoma. Clin Cancer Res, 6, pp. 3904-3909.
8. O'Keane, J. C., Mack, C., Lynch, E., Harrington, D. and Neiman, R. S. (1990) Prognostic correlation of HLA-DR expression in large cell lymphoma as determined by LN3 antibody staining. An Eastern Cooperative Oncology Group (ECOG) study. Cancer, 66, pp. 1147-1153.
9. Rimsza, L. M., Roberts, R. A., Campo, E., Grogan, T. M., Bea, S. and Salaverria, I. (2006) Loss of major histocompatibility class II expression in non-immune privileged site diffuse large B cell lymphoma is highly coordinated and not due to chromosomal deletions. Blood, 107, pp. 1101-1107.
10. Klimo, P. and Connors, J. M. (1985) Macop-B Chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Int Med, 102, pp. 596-602.
11. Gatter, J. C. and Warnke, R. A. (2001) Diffuse large B cell lymphoma. Pathology and Genetics, Tumours of Haematopoietic and Lymphoid Tissues, pp. 171-174. IARC Press, Lyon, France
12. Kaplan, E. L. and Meier, P. (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc, 53, pp. 457-481.
13. Shipp, M. A., Harrington, D. P., Anderson, J. R., Armitage, J. O., Bonadonna, G. and Brittinger, G. (1993) A predictive model for aggressive non-Hodgkins-lymphoma. N Engl J Med, 329, pp. 987-994.
14. Cox, D. R. (1972) Regression models and life tables. J Roy Stat Soc B, pp. 187-220.
15. Alizadeh, A. A., Eisen, M. B., Davis, R. E., Lossos, I. S. and Rosenwald, A. (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature, 403, pp. 503-511.
16. Hans, C. P., Weisenburger, D. D., Greiner, T. C., Gascoyne, R. D., Delabie, J. and Ott, G. (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood, 103, pp. 275-282.
17. Jordanova, E. S., Riemersma, S. A., Philippo, K., Giphart-Gassler, M., Schuuring, E. and Kluin, P. M. (2002) Hemizygous deletions in the HLA region account for loss of heterozygosity in the majority of diffuse large B-cell lymphomas of the testis and the central nervous system. Genes Chrom Cancer, 35, pp. 38-48.
18. Riemersma, S. A., Jordanova, E. S., Schop, R. F., Philippo, K., Looijenga, L. H. and Schuuring, E. (2000) Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites. Blood, 96, pp. 3569-3577.